Drug Trial Radar · NCT07859202
The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- GL Pharm Tech CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of W2505.
Conditions
- Erectile Dysfunctions
Interventions
W2505Drug
PO, Once daily(QD), 12 weeks
W2505-P1Drug
PO, Once daily(QD), 12 weeks
W2505-RDrug
PO, Once daily(QD), 12 weeks
W2505-P2Drug
PO, Once daily(QD), 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain ScoreTime frame: Baseline, Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Inha University Hospital
Incheon, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.